DelveInsight’s “Polymyositis Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of the Polymyositis, historical and forecasted epidemiology as well as the Polymyositis therapeutics market trends in the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.

Discover Key Insights into the Polymyositis Market with DelveInsight’s In-Depth Report @ Polymyositis Market Size

Key Takeaways from the Polymyositis Market Report

• In June 2025, EMD Serono Research & Development Institute Inc. announced a study is to evaluate the efficacy and safety of orally administered M5049 in idiopathic inflammatory myopathies, specifically dermatomyositis (DM) and polymyositis (PM) participants for 24 weeks.
• In June 2025, Cabaletta Bio announced a study is being conducted to evaluate the safety and efficacy of an investigational cell therapy, CABA-201, that can be given to patients with DM, ASyS, IMNM, or JIIM who have active disease. A single dose of CABA-201 in combination with cyclophosphamide (CY) and fludarabine (FLU) will be evaluated.
• In June 2025, NPO Petrovax conducted a clinical study is to evaluate the efficacy and safety of Longidaza®, lyophilisate for preparation of solution for injection, at a dose of 3000 IU compared to placebo in the treatment of adult patients with residual changes in the lungs after COVID-19 infection.
• In June 2025, argenx organized a study duration will be approximately 92 weeks for all participants. After the screening period, eligible participants will be randomized in a 2:1 ratio to receive either empasiprubart or placebo, respectively, during the treatment period (duration of 25 weeks). At the end of the treatment period, all the participants will enter a safety follow-up period (duration of 65 weeks).
• In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of Polymyositis in the 7MM were nearly 80 thousand in 2023.
• Among the European countries, Germany had the highest diagnosed prevalent cases of Polymyositis with ~9 thousand cases, followed by France, which had diagnosed prevalent population of ~7 thousand in 2023. On the other hand, Spain had the lowest prevalent population (3 thousand cases).
• Japan had nearly 12 thousand total diagnosed prevalent cases of Polymyositis in 2023, accounting for approximately 16% in 7MM.
• The DelveInsight analysis indicates that in Japan, females were more affected than males, with approximately 9 thousand female cases and 3 thousand male cases in 2023.
• The Polymyositis Companies such as Boehringer Ingelheim Pharmaceuticals, Mitsubishi Tanabe Pharma, Janssen Pharmaceutical, Kezar Life Sciences, Bristol-Myers Squibb, ONO Pharma, Horizon Therapeutics, Immunoforge, Restem, LLC., and Eli Lilly and Company, and others.
• Promising Polymyositis Therapies such as Efgartigimod, PF1801, tocilizumab, KZR-616, Adrenocorticotropic Hormone Gel, M5049 high dose, Tacrolimus, Rituximab, Froniglutide, PF-06823859, Abatacept subcutaneous, and others.

Stay ahead in the Polymyositis Therapeutics Market with DelveInsight’s Strategic Report @ Polymyositis Market Outlook

Polymyositis Epidemiology Segmentation in the 7MM

• Total Polymyositis Diagnosed Prevalent Cases
• Polymyositis Gender-specific Diagnosed Prevalent Cases
• Polymyositis Age-specific Diagnosed Prevalent Cases

Download the report to understand which factors are driving Polymyositis epidemiology trends @ Polymyositis Prevalence

Polymyositis Emerging Drugs

• SAPHNELO (Anifrolumab): AstraZeneca

SAPHNELO (anifrolumab) is a first-in-class, fully human monoclonal antibody that binds to subunit 1 of the type I interferon (IFN) receptor, blocking the activity of type I IFN. Type I IFNs, such as IFN-alpha, IFN-beta, and IFN-kappa, are cytokines involved in regulating the inflammatory pathways implicated in SLE. The majority of adults with SLE have increased type I IFN signaling, which is associated with increased disease activity and severity.

• Dazukibart (PF-06823859): Pfizer

The drug dazukibart (PF-06823859) is being developed to treat moderate to severe dermatomyositis and Polymyositis by Pfizer along with other indications like systemic lupus erythematosus, subacute cutaneous lupus erythematosus (SCLE), and chronic cutaneous lupus erythematosus (CCLE). Neutralizing antibodies against humanized immunoglobulin and a new biological entity (NBE) make up the therapeutic candidate. It works by specifically targeting interferon beta 1 (IFNB1) and is injected intravenously and subcutaneously.

Polymyositis Market Outlook

Polymyositis is an inflammatory muscle disease that requires a multifaceted approach to treatment, primarily focusing on reducing inflammation, managing symptoms, and preventing long-term complications. The mainstay of treatment is corticosteroids, such as prednisone, which are often administered as the first line of therapy due to their potent anti-inflammatory effects. These steroids are typically prescribed in high doses initially and gradually tapered based on the patient’s response. For patients who do not respond adequately to corticosteroids or who experience significant side effects, immunosuppressive agents such as methotrexate or azathioprine are commonly used. These medications help to modulate the immune system and can be used as steroid-sparing agents to reduce the dependency on corticosteroids.

Get In-Depth Knowledge on Polymyositis Market Trends and Forecasts with DelveInsight @ Polymyositis Treatment Market

Scope of the Polymyositis Market Report

• Coverage- 7MM
• Polymyositis Companies- Boehringer Ingelheim Pharmaceuticals, Mitsubishi Tanabe Pharma, Janssen Pharmaceutical, Kezar Life Sciences, Bristol-Myers Squibb, ONO Pharma, Horizon Therapeutics, Immunoforge, Restem, LLC., and Eli Lilly and Company, and others.
• Polymyositis Therapies- Efgartigimod, PF1801, tocilizumab, KZR-616, Adrenocorticotropic Hormone Gel, M5049 high dose, Tacrolimus, Rituximab, Froniglutide, PF-06823859, Abatacept subcutaneous, and others.
• Polymyositis Therapeutic Assessment: Polymyositis Current marketed and Polymyositis Emerging Therapies
• Polymyositis Market Dynamics: Polymyositis Market drivers and Polymyositis Market Barriers

Unlock Strategic Insights with DelveInsight’s Comprehensive Polymyositis Market Report @ Polymyositis Market Drivers and Barriers

Table of Content

1 Key Insights

2 Report Introduction

3 Polymyositis Market Overview at a Glance

4 Epidemiology and Market Forecast Methodology

5 Key Events

6 Executive Summary

7 Disease Background and Overview

8 Epidemiology and Patient Population of Polymyositis

9 Patient Journey

10 Emerging Therapies

11 Polymyositis: Seven Major Market Analysis

12 KOL Views

13 SWOT Analysis

14 Unmet needs

15 Market Access and Reimbursement

16 Appendix

17 Report Methodology

18 DelveInsight Capabilities

19 Disclaimer

18 Bibliography

19 DelveInsight Capabilities

20 Disclaimer

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/polymyositis-market